Amicus Therapeutics Inc (FOLD) Stock
FOLD is no longer traded. Amicus Therapeutics was acquired by BioMarin (BMRN) in April 2026.
Each FOLD share was exchanged for $14.50 in cash. Prices on this page are historical; the last trade was April 24, 2026 at $14.49.
See BioMarin (BMRN) stock →Amicus Therapeutics stock price history
FOLD final trading statistics
- Final close
- $14.49
- Final trading day
- Apr 24, 2026
- Market cap at delisting
- $4.55B
- Shares outstanding
- 314.00M
- Final 52-week range
- $5.51 – $14.50
- Avg. volume (final 3 mo.)
- 4,361,500
- All-time high (split-adj.)
- $24.89 · Dec 2020
- All-time low (split-adj.)
- $1.82 · Apr 2014
- Return since IPO
- +0.4%
- Beta
- 0.48
- Book value / share
- $0.88
- Price / book
- 16.43
Amicus Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $634.21M | -$27.1M | $0.20 |
| FY2024 | $528.29M | -$56.1M | $0.23 |
| FY2023 | $399.36M | -$151.6M | -$0.51 |
| FY2022 | $329.23M | -$236.6M | -$0.82 |
| FY2021 | $305.51M | -$250.5M | -$0.92 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
Amicus Therapeutics stock FAQ
What happened to Amicus Therapeutics stock?
Amicus Therapeutics was acquired by BioMarin (BMRN) in April 2026. Shareholders received $14.50 in cash for each share. FOLD stock stopped trading on the Nasdaq, with a final close of $14.49 on April 24, 2026.
What did Amicus Therapeutics shareholders receive?
Each FOLD share was converted into $14.50 in cash. The deal was valued at about $4.8 billion.
Is FOLD stock still trading?
No. FOLD was delisted from the Nasdaq in April 2026 and no longer trades on a U.S. exchange.
What was the last price of FOLD stock?
FOLD closed at $14.49 on its final trading day, April 24, 2026, for a market value of about $4.55B.
What were Amicus Therapeutics's revenue and earnings in its last full fiscal year?
Amicus Therapeutics reported revenue of $634.21M and net income of -$27.1M in fiscal 2025, its last full year as a public company.
When did Amicus Therapeutics go public?
Amicus Therapeutics Inc stock began trading on May 31, 2007.